Literature DB >> 15699476

Randomized phase II trials: what does randomization gain?

H Samuel Wieand.   

Abstract

Mesh：

Year:  2005        PMID： 15699476     DOI： 10.1200/JCO.2005.10.956

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).

Authors:  Kristie A Blum; Mei-Yin Polley; Sin-Ho Jung; Travis J Dockter; Sarah Anderson; Eric D Hsi; Nina Wagner-Johnston; Beth Christian; Jim Atkins; Bruce D Cheson; John P Leonard; Nancy L Bartlett
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

2.  To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs.

Authors:  Alyssa M Vanderbeek; Steffen Ventz; Rifaquat Rahman; Geoffrey Fell; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Neuro Oncol       Date:  2019-10-09       Impact factor: 12.300

Review 3.  Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?

Authors:  Peter H O'Donnell; Walter M Stadler
Journal:  Clin Cancer Res       Date:  2012-03-16       Impact factor: 12.531

4.  Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.

Authors:  Wei Jiang; Jo A Wick; Jianghua He; Jonathan D Mahnken; Matthew S Mayo
Journal:  J Biopharm Stat       Date:  2017-11-27       Impact factor: 1.051

5.  Randomized phase II trials: time for a new era in clinical trial design.

Authors:  Sumithra J Mandrekar; Daniel J Sargent
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

6.  Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Authors:  Cristina Iclozan; Scott Antonia; Alberto Chiappori; Dung-Tsa Chen; Dmitry Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2013-04-16       Impact factor: 6.968

7.  Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

Authors:  B M Wolpin; E M O'Reilly; Y J Ko; L S Blaszkowsky; M Rarick; C M Rocha-Lima; P Ritch; E Chan; J Spratlin; T Macarulla; E McWhirter; D Pezet; M Lichinitser; L Roman; A Hartford; K Morrison; L Jackson; M Vincent; L Reyno; M Hidalgo
Journal:  Ann Oncol       Date:  2013-02-28       Impact factor: 32.976

Review 8.  Randomized phase II designs.

Authors:  Larry Rubinstein; John Crowley; Percy Ivy; Michael Leblanc; Dan Sargent
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Current issues in oncology drug development, with a focus on Phase II trials.

Authors:  Daniel J Sargent; Jeremy M G Taylor
Journal:  J Biopharm Stat       Date:  2009       Impact factor: 1.051

10.  Statistical evaluation of the use of concurrent controls in treatment screening studies.

Authors:  Rickey E Carter; Qian Shi
Journal:  Clin Transl Sci       Date:  2013-04-19       Impact factor: 4.689
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.